Flumazenil: an unreliable antagonist in baclofen overdose
نویسندگان
چکیده
منابع مشابه
Baclofen overdose.
A 57-year-old woman suffering from multiple sclerosis took an estimated 1500 mg of baclofen. She became deeply unconscious with generalized flaccid muscle paralysis and absent tendon reflexes. Toxicological analysis confirmed the presence of baclofen together with small amounts of paracetamol and glutethimide. Supportive therapy, including assisted ventilation for 3 days, led to complete recove...
متن کاملMassive baclofen overdose.
A case is presented of a massive baclofen overdose with the highest blood baclofen concentrations currently reported. Interesting clinical features included profound hypotension, distributive shock and absent brainstem reflexes. Cerebral recovery was surprisingly slow but complete, and was then unexpectedly terminated by a sudden major splenic arterial haemorrhage followed by a severe haemorrha...
متن کاملAtropine treatment for baclofen overdose.
A healthy 17-year-old girl took a single large dose (420 mg) of baclofen. She was conscious on admission to hospital, but within 3.5 hr of overdose showed signs of marked cerebral, cardiac and respiratory depression, flaccidity and hypothermia. Eight hours after overdose, atropine administered i.v. produced a worth-while increase in cardiac output, ventilation and temperature, lasting for about...
متن کاملEFFICACY OF FLUMAZENIL IN THE MANAGEMENT OF BENZODIAZEPINE OVERDOSE
Benzodiazepine overdose is the most commonly encountered drug overdose in Iran. It has been reported by many authors that flumazenil possesses highly specific antagonistic activity on central benzodiazepine receptors. We conducted a prospective study on 150 patients brought to the toxicology emergency ward in Loghman-Hakim hospital with benzodiazepine overdose to assess the efficacy of flu...
متن کاملFlumazenil: A specific benzodiazepine antagonist
Flumazenil is a specific benzodiazepine (BZD) antagonist which inhibits the effects of BZD agonists by competing for the receptor site in the central nervous system. It has completed clinical trials in the United States and received final approval from the U.S. Food and Drug Administration for release in January 1992. Following intravenous injection, clinically apparent arousal usually occurs w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Anaesthesia
سال: 1996
ISSN: 0003-2409
DOI: 10.1111/j.1365-2044.1996.tb07796.x